Target intelligence / Profile preview

Japanese encephalitis virus membrane glycoprotein precursor (prM) (prM)

Target
prM
Molecular classification
Viral structural protein, Glycoprotein, Molecular chaperone
01

Overview

The Japanese encephalitis virus membrane glycoprotein precursor (prM) is a structural protein essential for the assembly and maturation of the Japanese encephalitis virus (JEV) (UniProt P27395). It acts as a chaperone for the envelope (E) protein, forming a prM-E heterodimer that prevents the E protein from undergoing premature fusion in the acidic environment of the secretory pathway (PubMed: 12134023). During viral egress, prM is cleaved by the host cell protease furin into the mature M protein and a pr peptide, a step necessary for the virus to become infectious (PubMed: 25100874). This protein is a primary component in several JEV vaccines, such as Ixiaro and IMOJEV, which aim to induce neutralizing antibodies against the viral surface (CDC, 2023). While prM itself is not typically the sole target of small-molecule antivirals, its role in maturation makes it a focal point for research into furin inhibitors and therapeutic antibodies (PubMed: 31235547). Understanding prM's function is vital for addressing Japanese encephalitis, a leading cause of viral encephalitis in Asia (WHO, 2022). The transition from prM to M is a hallmark of flavivirus maturation and represents a vulnerable stage in the viral life cycle. Therapeutic strategies often focus on the prM-E complex because it is the most exposed and immunologically relevant structure on the immature virion.

Other names
Pre-membrane proteinprM proteinMembrane protein precursorJEV prM
02

Mechanism of action

Vaccine-induced neutralizing antibodies target the prM/E complex to prevent viral entry; experimental furin inhibitors block the cleavage of prM into mature M protein to prevent viral infectivity.

03

Biological functions

Viral assemblyViral maturationProtein foldingProtection of envelope proteinHost cell protease substrate
04

Disease associations

Japanese encephalitisViral infectionNeurological disease
05

Safety considerations

Antibody-dependent enhancement (ADE)Cross-reactivity with other flavivirusesHypersensitivity to vaccine componentsNeurovirulence of live-attenuated strains
06

Interacting drugs

Ixiaro

3 more in the full profile.

07

Biomarkers

Anti-prM IgM antibodiesAnti-prM IgG antibodiesJEV RNAPlaque Reduction Neutralization Test (PRNT) titers

Beyond the preview

Go deeper on Japanese encephalitis virus membrane glycoprotein precursor (prM) (prM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japanese encephalitis virus membrane glycoprotein precursor (prM) (prM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call